Announcements Trials
Browse Landscape

Phase

Phase 1 2

Status

Completed 1Active not recruiting 1

Sponsor Class

INDUSTRY 2

Study Type

Interventional 2

Sponsor

Cancer Type

Sarcoma 2Genitourinary 2Thoracic 1Lymphoid 1Gynecologic 1Gastrointestinal 1CNS 1Breast 1

Conditions

Recurrence 3Neoplasms 3Glioma 3Triple Negative Breast Neoplasms 2Sarcoma 2Multiple Myeloma 2Lymphoma, Non-Hodgkin 2Lymphoma 2Wilms Tumor 1Waldenstrom Macroglobulinemia 1Sarcoma, Synovial 1Sarcoma, Ewing 1Rhabdomyosarcoma 1Rhabdoid Tumor 1Prostatic Neoplasms 1Paraproteinemias 1Ovarian Neoplasms 1Osteosarcoma 1Neuroectodermal Tumors, Primitive 1Neuroblastoma 1Neoplasms, Plasma Cell 1Neoplasms, Neuroepithelial 1Medulloblastoma 1Lymphoproliferative Disorders 1Lymphoma, Mantle-Cell 1Lymphoma, Large B-Cell, Diffuse 1Lymphoma, B-Cell, Marginal Zone 1Leukemia, Lymphocytic, Chronic, B-Cell 1Immunoproliferative Disorders 1Hodgkin Disease 1

Interventions

Doxorubicin 141Ifosfamide 85Radiotherapy 80Cyclophosphamide 72Gemcitabine 63Filgrastim 54pembrolizumab 43pazopanib 39Etoposide 39Docetaxel 39Vincristine 37Cisplatin 35Trabectedin 32Nivolumab 32Irinotecan 26Magnetic Resonance Spectroscopy 25Carboplatin 25Temozolomide 23Ipilimumab 22Bevacizumab 20Radiation 19Surgical Procedures, Operative 18Granulocyte Colony-Stimulating Factor 18Sirolimus 17Mesna 17Melphalan 17Dactinomycin 17Biopsy 17eribulin 16anlotinib 16

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Interventional × Sarcoma × CLR1404 × Clear all
NCT03478462 2026-03-18

CLOVER-2

Cellectar Biosciences, Inc.

Phase 1 Active not recruiting
30 enrolled
CNSGenitourinaryLymphoidSarcoma

Diffuse Intrinsic Pontine Glioma, Ependymoma, Glioblastoma, Glioma, Hodgkin Disease, Lymphoma, Lymphoma, Non-Hodgkin, Medulloblastoma, Wilms Tumor, Neuroblastoma, Rhabdomyosarcoma, Sarcoma, Sarcoma, Ewing, Osteosarcoma, Sarcoma, Synovial, Neuroectodermal Tumors, Primitive, Neoplasms, Neuroepithelial, Gliosarcoma, Rhabdoid Tumor, Desmoplastic Small Round Cell Tumor

NCT01495663 2015-02-26

Dose Escalation Study of I-131-CLR1404 in Subjects With Cancer That Does Not Respond to Treatment or Has Returned

Cellectar Biosciences, Inc.

Phase 1 Completed
12 enrolled
BreastGastrointestinalGenitourinaryGynecologicSarcomaThoracic

Carcinoma, Non-Small-Cell Lung, Esophageal Neoplasms, Neoplasms, Ovarian Neoplasms, Prostatic Neoplasms, Recurrence, Sarcoma, Colorectal Neoplasms, Triple Negative Breast Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡